ハイリスク患者のがん薬物療法ハンドブック

出版社： 羊土社
著者：
発行日： 2017-08-10
分野： 臨床医学：一般  >  癌/腫瘍一般
ISBN： 9784758118149
電子書籍版： 2017-08-10 （第1版第2刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,730 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,730 円(税込)

購入する

商品紹介

心疾患合併，PS不良，うつなど，多様化する患者の背景にあったがん薬物療法の進め方を，１冊に凝縮．「注意すべき薬物相互作用は？」「既往症とがんのどちらの治療を優先するか？」などの疑問に，現場目線で解説．

目次

  • ハイリスク患者のがん薬物療法ハンドブック

    ―目次―

    第1章　配慮を要する患者でのがん薬物療法
    　1. 高齢
    　2. うつ
    　3. 肥満
    　4. 妊娠・授乳
    　5. 妊孕性の温存
    　6. 社会的な配慮

    第2章　副作用リスクを高める病態でのがん薬物療法
    　A．循環器疾患
    　　1. 高血圧
    　　2. 不整脈
    　　3. 虚血性心疾患
    　　4. 血栓症
    　　5. 心不全
    　B．消化器疾患
    　　1. 胃十二指腸潰瘍
    　　2. 下痢・便秘・炎症性腸疾患（IBD）
    　C．肝疾患
    　　1. 肝機能障害
    　　2. ウィルス肝炎（主にB型）
    　D．腎疾患
    　　1. 腎機能障害
    　　2. 電解質異常
    　　3. ネフローゼ症候群
    　E．呼吸器疾患
    　　1. 間質性肺炎
    　　2. COPD・気管支喘息
    　F．神経系疾患
    　　1. 脳血管障害
    　　2. 末梢神経障害
    　　3. 筋疾患
    　　4. 痙攣
    　G．内分泌・代謝疾患
    　　1. 糖尿病
    　　2. 骨粗鬆症
    　　3. 甲状腺機能低下症
    　　4. 高尿酸血症
    　H．膠原病・リウマチ性疾患
    　　1. 膠原病・リウマチ性疾患
    　I．血液疾患
    　　1. 貧血
    　　2. 特発性血小板減少（ITPなど）
    　　3. 骨髄異形成症候群（MDS）
    　J．感染症
    　　1. かぜ症候群
    　　2. 結核・非結核性抗酸菌症
    　K．眼科疾患
    　　1. 緑内障・白内障・硝子体疾患

    第3章　見過ごせない臨床背景とがん薬物療法
    　1. 周術期
    　2. 薬物相互作用
    　3. ポリファーマシー

    第4章　特殊な臨床背景でのがん薬物療法
    　1. PS不良例
    　2. 重複がん・多発がん
    　3. 多量腹水・多量胸水
    　4. 摂食・嚥下困難
    　5. 凝固異常症
    　6. 歯科治療中
    　7. 長期にわたるステロイド内服患者

    ◆ 付録1：自習のための確認問題
    ◆ 付録2：抗がん薬の薬物相互作用

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 配慮を要する患者でのがん薬物療法

P.21 掲載の参考文献
1) 「がん情報サービス がん登録・統計」(国立がん研究センター がん対策情報センター):http://ganjoho.jp/reg_stat/index.html
 
2) 林 直美, 安藤雄一:がん領域における包括的高齢者評価の臨床応用の可能性. 週刊日本医事新報, 4775:25-31, 2015
 
3) 「肺癌診療ガイドライン 2016年版」(日本肺癌学会/編), p100, 金原出版, 2016
 
4) 「肺癌診療ガイドライン 2016年版」(日本肺癌学会/編), p122, 金原出版, 2016
 
5) 「肺癌診療ガイドライン 2016年版」(日本肺癌学会/編), p125, 金原出版, 2016
 
6) 「肺癌診療ガイドライン 2016年版」(日本肺癌学会/編), p131, 金原出版, 2016
 
7) 「肺癌診療ガイドライン 2016年版」(日本肺癌学会/編), p137, 金原出版, 2016
 
8) 「乳癌診療ガイドライン1 治療編 2015年版」(日本乳癌学会/編), p112, 金原出版, 2015
 
9) 「胃癌治療ガイドライン 医師用 2014年5月改訂」(日本胃癌学会/編), p39, 2014
 
10) Bando H, et al:Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer, 19:919-926, 2016
 
11) 「大腸癌治療ガイドライン 医師用 2016年版」(大腸癌研究会/編), p63, 2016
 
12) Thieblemont C & Coiffier B:Lymphoma in Older Patients. J Clin Oncol, 25:1916-1923, 2007
PubMed
13) Peyrade F, et al:Attenuated immunochemotherapy regimen (R-miniCHOP)in elderly patients older than 80 years with diffuse large B-cell lymphoma:a multicentre, single-arm, phase 2 trial. Lancet Oncol, 12:460-468, 2011
PubMed
14) Hurria A, et al:Developing a cancer-specific geriatric assessment:a feasibility study. Cancer, 104:1998-2005, 2005
PubMed
P.31 掲載の参考文献
1) Akechi T, et al:Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients:associated and predictive factors. J Clin Oncol, 22:1957-1965, 2004
PubMed
2) Derogatis LR, et al:The prevalence of psychiatric disorders among cancer patients. JAMA, 249:751-757, 1983
PubMed
3) Minagawa H, et al:Psychiatric morbidity in terminally ill cancer patients. A prospective study. Cancer, 78:1131-1137, 1996
PubMed
4) Fang F, et al:Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med, 366:1310-1318, 2012
PubMed
5) Passik SD, et al:Oncologists' recognition of depression in their patients with cancer. J Clin Oncol, 16:1594-1600, 1998
 
6) 「日本医薬品集 医療薬 2016」(日本医薬品集フォーラム/監), じほう, 2015
 
7) Schellander R & Donnerer J:Antidepressants:clinically relevant drug interactions to be considered. Pharmacology, 86:203-215, 2010
PubMed
8) Kelly CM, et al:Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen:a population based cohort study. BMJ, 340:c693, 2010
PubMed
9) Cronin-Fenton DP & Lash TL:Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes. Expert Rev Clin Pharmacol, 4:363-377, 2011
PubMed
10) L'Esperance S, et al:Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors:CEPO review and recommendations. Support Care Cancer, 21:1461-1474, 2013
PubMed
11) Maenpaa J, et al:Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine. Clin Pharmacol Ther, 61:225, 1997
 
12) Yap KY, et al:Clinically relevant drug interactions between anticancer drugs and psychotropic agents. Eur J Cancer Care (Engl), 20:6-32, 2011
PubMed
13) Zigmond AS & Snaith RP:The hospital anxiety and depression scale. Acta Psychiatr Scand, 67:361-370, 1983
PubMed
14) Akizuki N, et al:Development of an Impact Thermometer for use in combination with the Distress Thermometer as a brief screening tool for adjustment disorders and/or major depression in cancer patients. J Pain Symptom Manage, 29:91-99, 2005
PubMed
15) Okamura M, et al:Clinical experience of the use of a pharmacological treatment algorithm for major depressive disorder in patients with advanced cancer. Psychooncology, 17:154-160, 2008
PubMed
16) [Depression in adults with a chronic physical health problem:recognition and management(Clinical guideline 91)]:https://www.nice.org.uk/guidance/CG91
 
P.37 掲載の参考文献
1) Matsuo K, et al:Association between body mass index and the colorectal cancer risk in Japan:pooled analysis of population-based cohort studies in Japan. Ann Oncol, 23:479-490, 2012
PubMed
2) Wada K, et al:Body mass index and breast cancer risk in Japan:a pooled analysis of eight population-based cohort studies. Ann Oncol, 25:519-524, 2014
PubMed
3) Bhaskaran K, et al:Body-mass index and risk of 22 specific cancers:a population-based cohort study of 5・24 million UK adults. Lancet, 384:755-765, 2014
 
4) Field KM, et al:Chemotherapy dosing strategies in the obese, elderly, and thin patient:results of a nationwide survey. J Oncol Pract, 4:108-113, 2008
PubMed
5) Lu Y, et al:Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer. J Clin Oncol, 29:3358-3365, 2011
PubMed
6) Meyerhardt JA, et al:Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer, 98:484-495, 2003
PubMed
7) Zhang M, et al:Body mass index in relation to ovarian cancer survival. Cancer Epidemiol Biomarkers Prev, 14:1307-1310, 2005
PubMed
8) Georgiadis MS, et al:Obesity and therapy-related toxicity in patients treated for small-cell lung cancer. J Natl Cancer Inst, 87:361-366, 1995
PubMed
9) Wright JD, et al:Carboplatin dosing in obese women with ovarian cancer:a Gynecologic Oncology Group study. Gynecol Oncol, 109:353-358, 2008
 
10) Griggs JJ, et al:Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med, 165:1267-1273, 2005
PubMed
11) Colleoni M, et al:Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet, 366:1108-1110, 2005
PubMed
12) Griggs JJ, et al:Appropriate chemotherapy dosing for obese adult patients with cancer:American Society of Clinical Oncology clinical practice guideline. J Clin Oncol, 30:1553-1561, 2012
 
13) Rosner GL, et al:Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer:results from cancer and leukemia group B study 8541. J Clin Oncol, 14:3000-3008, 1996
 
14) Barrett SV, et al:Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol, 19:898-902, 2008
PubMed
15) Wilhelm SM & Kale-Pradhan PB:Estimating creatinine clearance:a meta-analysis. Pharmacotherapy, 31:658-664, 2011
PubMed
16) Nyman HA, et al:Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing:an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy, 31:1130-1144, 2011
 
17) Demirovic JA, et al:Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm, 66:642-648, 2009
PubMed
18) Sparreboom A, et al:Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol, 25:4707-4713, 2007
PubMed
P.47 掲載の参考文献
1) Pereg D, et al:Cancer in pregnancy:gaps, challenges and solutions. Cancer Treat Rev, 34:302-312, 2008
PubMed
2) 「妊娠と授乳 第2版」(伊藤真也, 村島温子/編), 南山堂, 2014
 
3) Lambertini M, et al:Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev, 41:301-309, 2015
PubMed
4) 「産婦人科診療ガイドライン産科編2014」(日本産科婦人科学会/日本産婦人科医会/編・監), pp66, 109 日本産科婦人科学会, 2014
 
5) Pasternak B, et al:Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med, 368:814-823, 2013
PubMed
6) [Drugs in Pregnancy and Lactation tenth Edition](GG Brggs & RK Freeman, eds), Wolters Kluwer, 2014
 
7) Park-Wyllie L, et al:Birth defects after maternal exposure to corticosteroids:prospective cohort study and meta-analysis of epidemiological studies. Teratology, 62:385-392, 2000
PubMed
8) Amant F, et al:Breast cancer in pregnancy. Lancet, 379:570-579, 2012
PubMed
9) Boxer LA, et al:Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia. Obstet Gynecol, 125:197-203, 2015
PubMed
10) Li DK, et al:Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage:population based cohort study. BMJ, 327:368, 2003
PubMed
11) 「向精神薬と妊娠・授乳」(伊藤真也, 他/編), pp58-62, 南山堂, 2014
 
12) [Medications & Mother's Milk 2014](TW Hale & HE Rowe, eds), Hale Pub, 2014
 
13) 日置三紀, 他:浸潤性子宮頸がん合併妊娠における術前化学療法に対する薬学的介入の一例. 第3回日本臨床腫瘍薬学会学術大会, 2015
 
P.54 掲載の参考文献
1) 「乳がん患者の妊娠出産と生殖医療に関する診療の手引き 2014年版」(「乳癌患者における妊孕性保持支援のための治療選択および患者支援プログラム・関係ガイドラインの開発」班, 日本がん・生殖医療研究会/編), 金原出版, 2014
 
2) Wallace WH, et al:Fertility preservation for young patients with cancer:who is at risk and what can be offered? Lancet Oncol, 6:209-218, 2005
PubMed
3) Loren AW, et al:Fertility preservation for patients with cancer:American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol, 31:2500-2510, 2013
 
4) Moore HC, et al:Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med, 372:923-932, 2015
PubMed
P.59 掲載の参考文献
1) 「高額療養費制度を利用される皆さまへ」(厚生労働省):http://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryouhoken/juuyou/kougakuiryou/index.html
 
2) 「事業場における治療と職業生活の両立支援のためのガイドライン」(厚生労働省), pp22-23, 2016:http://www.mhlw.go.jp/stf/houdou/0000113365.html
 
3) 「がん患者が就労継続しやすい愛知づくりに向けた提言」(愛知県):http://www.pref.aichi.jp/soshiki/kenkotaisaku/0000081063.html
 
4) Hyodo I, et al:Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol, 23:2645-2654, 2005
PubMed
5) Rancati T, et al:Factors predicting radiation pneumonitis in lung cancer patients:a retrospective study. Radiother Oncol, 67:275-283, 2003
PubMed
6) Ruddy K, et al:Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin, 59:56-66, 2009
PubMed

第2章 副作用リスクを高める病態でのがん薬物療法

P.68 掲載の参考文献
1) Brinda BJ, et al:Anti-VEGF-Induced Hypertension:a Review of Pathophysiology and Treatment Options. Curr Treat Options Cardiovasc Med, 18:33, 2016
PubMed
2) Tomita Y, et al:Key predictive factors of axitinib(AG-013736)-induced proteinuria and efficacy:a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer, 47:2592-2602, 2011
PubMed
3) Li W, et al:Vascular and Metabolic Implications of Novel Targeted Cancer Therapies:Focus on Kinase Inhibitors. J Am Coll Cardiol, 66:1160-1178, 2015
PubMed
4) Herrmann J, et al:Vascular Toxicities of Cancer Therapies:The Old and the New--An Evolving Avenue. Circulation, 133:1272-1289, 2016
PubMed
5) An MM, et al:Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab:an updated meta-analysis. Eur J Clin Pharmacol, 66:813-821, 2010
PubMed
6) Cai J, et al:Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab:a systematic review and meta-analysis. World J Surg Oncol, 11:306, 2013
PubMed
7) Azizi M, et al:Home blood-pressure monitoring in patients receiving sunitinib. N Engl J Med, 358:95-97, 2008
PubMed
8) Rini BI, et al:Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst, 103:763-773, 2011
PubMed
9) Motzer RJ, et al:Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma:overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol, 14:552-562, 2013
PubMed
10) Rini BI, et al:Axitinib dose titration:analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma. Ann Oncol, 26:1372-1377, 2015
PubMed
11) Grothey A, et al:Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT):an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381:303-312, 2013
PubMed
12) Demetri GD, et al:Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib(GRID):an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 381:295-302, 2013
PubMed
13) Schlumberger M, et al:Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med, 372:621-630, 2015
PubMed
14) Yeh ET & Bickford CL:Cardiovascular complications of cancer therapy:incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol, 53:2231-2247, 2009
PubMed
15) 「高血圧治療ガイドライン2014」(日本高血圧学会高血圧治療ガイドライン作成委員会/編), pp31-38, ライフサイエンス出版, 2014
 
16) James PA, et al:2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee(JNC 8). JAMA, 311:507-520, 2014
 
P.76 掲載の参考文献
1) Tamargo J, et al:Cancer chemotherapy and cardiac arrhythmias:a review. Drug Saf, 38:129-152, 2015
PubMed
2) Kannankeril P, et al:Drug-induced long QT syndrome. Pharmacol Rev, 62:760-781, 2010
PubMed
3) Yeh ET & Bickford CL:Cardiovascular complications of cancer therapy:incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol, 53:2231-2247, 2009
PubMed
4) Barbey JT, et al:Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol, 21:3609-3615, 2003
PubMed
5) Soignet SL, et al:United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol, 19:3852-3860, 2001
 
6) Arbuck SG, et al:A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr,:117-130, 1993
PubMed
7) Floyd JD, et al:Cardiotoxicity of cancer therapy. J Clin Oncol, 23:7685-7696, 2005
PubMed
8) 「腫瘍崩壊症候群(TLS)診療ガイダンス」(日本臨床腫瘍学会/編), pp4-7, 金原出版, 2013
 
9) 「重篤副作用疾患マニュアル 腫瘍崩壊症候群」(厚生労働省), pp9-13:http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1e17.pdf
 
10) Zang J, et al:Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib:a systematic review and meta-analysis. PLoS One, 7:e30353, 2012
PubMed
11) Zipes DP, et al:ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation, 114:e385-e484, 2006
PubMed
12) 「頭頸部がん薬物療法ガイダンス」(日本臨床腫瘍学会/編), pp30-38, 金原出版, 2015
 
13) 「造血器腫瘍診療ガイドライン 2013年版」(日本血液学会/編), p47, 金原出版, 2013
 
14) 「造血細胞移植ガイドライン 移植前処置(2014年10月)」(日本造血細胞移植学会/編), p27:https://www.jshct.com/guideline/guidelines_nm.shtml
 
P.82 掲載の参考文献
1) de Forni M, et al:Cardiotoxicity of high-dose continuous infusion fluorouracil:a prospective clinical study. J Clin Oncol, 10:1795-1801, 1992
PubMed
2) Van Cutsem E, et al:Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol, 13:484-485, 2002
PubMed
3) Tamargo J, et al:Cancer chemotherapy and cardiac arrhythmias:a review. Drug Saf, 38:129-152, 2015
PubMed
4) Polk A, et al:Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine:a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev, 39:974-984, 2013
 
5) Gradishar WJ & Vokes EE:5-Fluorouracil cardiotoxicity:a critical review. Ann Oncol, 1:409-414, 1990
PubMed
6) Khan MA, et al:A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital &Research Center. J Pak Med Assoc, 62:430-434, 2012
 
7) Coughlin S, et al:Capecitabine induced vasospastic angina. Int J Cardiol, 130:e34-e36, 2008
PubMed
8) Ng M, et al:The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer, 41:1542-1546, 2005
PubMed
9) Yeh ET & Bickford CL:Cardiovascular complications of cancer therapy:incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol, 53:2231-2247, 2009
PubMed
10) Herrmann J, et al:Vascular Toxicities of Cancer Therapies:The Old and the New--An Evolving Avenue. Circulation, 133:1272-1289, 2016
PubMed
11) Saif MW, et al:Fluoropyrimidine-associated cardiotoxicity:revisited. Expert Opin Drug Saf, 8:191-202, 2009
PubMed
12) Rosa GM, et al:Update on cardiotoxicity of anti-cancer treatments. Eur J Clin Invest, 46:264-284, 2016
PubMed
13) Jensen SA & Sorensen JB:Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol, 58:487-493, 2006
 
P.90 掲載の参考文献
1) Silverstein MD, et al:Trends in the incidence of deep vein thrombosis and pulmonary embolism:a 25-year population-based study. Arch Intern Med, 158:585-593, 1998
PubMed
2) Sallah S, et al:Venous thrombosis in patients with solid tumors:determination of frequency and characteristics. Thromb Haemost, 87:575-579, 2002
PubMed
3) Blom JW, et al:Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA, 293:715-722, 2005
PubMed
4) Palumbo A, et al:Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 22:414-423, 2008
PubMed
5) 「多発性骨髄腫に対するサリドマイドの適正使用ガイドライン」(日本臨床血液学会医薬品等適正使用評価委員会), p21:http://www.mhlw.go.jp/houdou/2004/12/h1210-2.html
 
6) Leleu X, et al:Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma:Intergroupe Francophone du Myelome 2009-02. Blood, 121:1968-1975, 2013
 
7) San Miguel J, et al:Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003):a randomised, open-label, phase 3 trial. Lancet Oncol, 14:1055-1066, 2013
 
8) Lyman GH, et al:Venous thromboembolism prophylaxis and treatment in patients with cancer:American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol, 31:2189-2204, 2013
 
9) Li W, et al:Vascular and Metabolic Implications of Novel Targeted Cancer Therapies:Focus on Kinase Inhibitors. J Am Coll Cardiol, 66:1160-1178, 2015
PubMed
10) Scappaticci FA, et al:Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst, 99:1232-1239, 2007
PubMed
11) Moore MJ, et al:Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 25:1960-1966, 2007
 
12) Yeh ET & Bickford CL:Cardiovascular complications of cancer therapy:incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol, 53:2231-2247, 2009
PubMed
13) Dimopoulos MA, et al:Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia, 28:1573-1585, 2014
 
14) Leleu X, et al:MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost, 110:844-851, 2013
PubMed
15) Larocca A, et al:Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 119:933-9; quiz 1093, 2012
 
16) Sun JM, et al:Unsuspected pulmonary emboli in lung cancer patients:the impact on survival and the significance of anticoagulation therapy. Lung Cancer, 69:330-336, 2010
 
P.100 掲載の参考文献
1) Ewer MS & Lippman SM:Type II chemotherapy-related cardiac dysfunction:time to recognize a new entity. J Clin Oncol, 23:2900-2902, 2005
PubMed
2) Baselga J, et al:Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med, 366:109-119, 2012
PubMed
3) 「シスプラチン投与におけるショートハイドレーション法の手引き」(日本肺癌学会ガイドライン検討委員会 ショートハイドレーションに関わる手引き作成チーム/編), pp4-5, 2015:https://www.haigan.gr.jp/uploads/photos/1022.pdf
 
4) Salvatorelli E, et al:Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart:implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther, 318:424-433, 2006
PubMed
5) Tamargo J, et al:Cancer chemotherapy and cardiac arrhythmias:a review. Drug Saf, 38:129-152, 2015
PubMed
6) Untch M, et al:First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer:cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol, 28:1473-1480, 2010
 
7) Gryn J, et al:Pentostatin increases the acute toxicity of high dose cyclophosphamide. Bone Marrow Transplant, 12:217-220, 1993
PubMed
8) Schwartz RG, et al:Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med, 82:1109-1118, 1987
PubMed
9) Martin M, et al:Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab:review and expert recommendations. Oncologist, 14:1-11, 2009
PubMed
10) 「乳癌診療ガイドライン1 治療編 2015年版」(日本乳癌学会/編), p88, 金原出版, 2015
 
11) Guarneri V, et al:Long-term cardiac tolerability of trastuzumab in metastatic breast cancer:the M.D. Anderson Cancer Center experience. J Clin Oncol, 24:4107-4115, 2006
 
12) Khaled HM, et al:A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients:long-term results. Ann Oncol, 10:1489-1492, 1999
PubMed
13) Wilson WH, et al:Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas:a pharmacodynamic approach with high efficacy. Blood, 99:2685-2693, 2002
 
14) 「造血器腫瘍診療ガイドライン 2013年版」(日本血液学会/編), pp203-204, 金原出版, 2013
 
15) Tsurumi H, et al:Biweekly CHOP or THP-COP regimens in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. A comparison of doxorubicin and pirarubicin:a randomized phase II study. J Cancer Res Clin Oncol, 130:107-113, 2004
 
16) 「乳癌診療ガイドライン1 治療編 2015年版」(日本乳癌学会/編), pp112-115, 金原出版, 2015
 
17) Jones S, et al:Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide:7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol, 27:1177-1183, 2009
PubMed
P.105 掲載の参考文献
1) 塩川優一, 他:非ステロイド性抗炎症剤による上部消化管傷害に関する疫学調査. リウマチ, 31:96-111, 1991
 
2) Wolfe MM, et al:Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med, 340:1888-1899, 1999
PubMed
3) Piper JM, et al:Corticosteroid use and peptic ulcer disease:role of nonsteroidal anti-inflammatory drugs. Ann Intern Med, 114:735-740, 1991
PubMed
4) 「重大な副作用回避のための服薬指導情報【第1集】」(日本病院薬剤師会/編), pp113-115, じほう, 1997
 
5) Slavin RE, et al:Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols:a clinical-pathologic study of 33 patients. Cancer, 42:1747-1759, 1978
PubMed
6) Suda K, et al:Continuous 5-fluorouracil infusion causing acute gastric mucosal lesions. Endoscopy, 25:426-427, 1993
PubMed
7) Lewis JH:Gastrointestinal injury due to medicinal agents. Am J Gastroenterol, 81:819-834, 1986
PubMed
8) Sartori S, et al:Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol, 18:463-467, 2000
 
P.112 掲載の参考文献
1) 「重篤副作用疾患別対応マニュアル 麻痺性イレウス」(厚生労働省):http://www.pmda.go.jp/files/000145979.pdf
 
2) Benson AB, et al:Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol, 22:2918-2926, 2004
PubMed
3) Gyawali B, et al:Opioid-induced constipation. Scand J Gastroenterol, 50:1331-1338, 2015
PubMed
4) Katakami N, et al:Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Cancer. J Clin Oncol, 35:1921-1928, 2017
 
P.117 掲載の参考文献
1) 「B型肝炎治療ガイドライン(第2.2版)」(日本肝臓学会 肝炎診療ガイドライン作成委員会/編), pp66-67, 2016:http://www.jsh.or.jp/files/uploads/HBV_GL_ver2.2_May30.pdf
 
2) 「ネクサバール適正使用ガイド 肝細胞癌編」, pp26-29, バイエル薬品
 
P.135 掲載の参考文献
1) 「B型肝炎治療ガイドライン(第2.2版)」(日本肝臓学会 肝炎診療ガイドライン作成委員会/編), pp66-67, 2016:http://www.jsh.or.jp/files/uploads/HBV_GL_ver2.2_May30.pdf
 
2) Umemura T & Kiyosawa K:Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med, 45:747-748, 2006
 
3) Dervite I, et al:Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med, 344:68-69, 2001
 
4) Kusumoto S, et al:Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol, 90:13-23, 2009
PubMed
5) ティーエスワンの使用上の注意の改訂について:http://di.taiho.co.jp/taiho/hp/fileDownloadMediaRevision.do?_revisionCode=20130601
 
6) Vento S, et al:Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet, 347:92-93, 1996
PubMed
P.143 掲載の参考文献
1) 日本腎臓学会, 他:がん薬物療法時の腎機能低下予防. 「がん薬物療法時の腎障害診療ガイドライン2016」(日本腎臓学会, 他/編集), pp15-43, 2016
 
2) 村上尚加, 陶山浩一:血液透析中の化学療法. 「ハイリスクがん患者の化学療法ナビゲーター」(高野利実/編), pp24-39, 2013
 
3) 「シスプラチン投与におけるショートハイドレーション法の手引き」(日本肺癌学会ガイドライン検討委員会 ショートハイドレーションにかかわる手引き作成チーム/編), pp1-5, 2015:https://www.haigan.gr.jp/uploads/photos/1022.pdf
 
4) Calvert AH, et al:Carboplatin dosage:prospective evaluation of a simple formula based on renal function. J Clin Oncol, 7:1748-1756, 1989
PubMed
5) Carboplatin dosing(U.S. Food and Drug Administration):http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm228974.htm
 
6) 「腎機能低下時に最も注意の必要な薬剤投与一覧(2016改訂27版)」(日本腎臓病薬物療法学会):http://jsnp.org/docs/yakuzai_dosing_27.pdf
 
7) がん診療 UP TO DATE 編集委員会:5章-14. 腎毒性. 「がん診療 UP TO DATE」(がん診療UP TO DATE編集委員会/編著), pp848-860, 日経BP社, 2013
 
8) Miller AA, et al:Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction:CALGB 60301. J Clin Oncol, 27:1800-1805, 2009
PubMed
9) 日本腎臓学会, 他:がん薬物療法時の腎機能低下予防. 「がん薬物療法時の腎障害診療ガイドライン2016」(日本腎臓学会, 他/編集), pp2-7, 2016
 
10) Ando Y, et al:Carboplatin dosing for adult Japanese patients. Nagoya J Med Sci, 76:1-9, 2014
PubMed
11) 「スペシャル・ポピュレーションへの抗がん薬用量調節ハンドブック」(谷川原祐介/監修, 今村知世/著), 南山堂, 2010
 
12) Fujita K, et al:Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure. Pharm Res, 33:269-282, 2016
PubMed
13) [NCCN Chemotherapy Order Templates(NCCN Templates(R))](Naional Comprehensive Cancer Network):http://www.nccn.org/ordertemplates/
 
14) 平田純生, 他:血液透析による薬物除去率に影響する要因. TDM研究, 22:141-142, 2005
Medical*Online
P.150 掲載の参考文献
1) 腫瘍随伴症候群. 「メルクマニュアル18版 日本語版」(Mark H. Beers 他, 著):http://merckmanual.jp/mmpej/sec11/ch147/ch147e.html?qt=%E8%85%AB%E7%98%8D%E9%9A%8F%E4%BC%B4&alt=sh
 
2) 「癌患者の栄養管理-癌悪液質の対策」(漆崎一朗/監), pp94-99, メディカルレビュー社, 1994
 
3) 「腫瘍崩壊症候群(TLS)診療ガイダンス」(日本臨床腫瘍学会/編), 金原出版, pp4-7, 2013
 
4) 柴田浩行:腫瘍随伴症候群 がんと電解質異常. 癌と化学療法, 37:1006-1010, 2010
 
5) 藤川太郎, 他:シスプラチン使用後に塩類喪失性腎症による著しい低ナトリウム血症を来した中咽頭癌症例. 日本耳鼻咽喉科学会会報, 118:1046-1052, 2015
Medical*Online
6) Yamada Y, et al:Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol, 26:141-148, 2015
 
7) がん診療UP TO DATE編集委員会:7章-6. SIADH. 「がん診療UP TO DATE」(がん診療UP TO DATE編集委員会/編著), pp986-993, 2013
 
8) Lajer H & Daugaard G:Cisplatin and hypomagnesemia. Cancer Treat Rev, 25:47-58, 1999
PubMed
9) 「シスプラチン投与におけるショートハイドレーション法の手引き」(日本肺癌学会ガイドライン検討委員会 ショートハイドレーションに関わる手引き作成チーム/編), pp1-5, 2015:https://www.haigan.gr.jp/uploads/photos/1022.pdf
 
10) 中根 実:腫瘍崩壊症候群. 「がんエマージェンシー」(中根 実/著), pp74-98, 2015
 
11) Sekine I, et al:Bodyweight change during the first 5 days of chemotherapy as an indicator of cisplatin renal toxicity. Cancer Sci, 98:1408-1412, 2007
PubMed
12) がん診療UP TO DATE 編集委員会:5章-14. 腎毒性. 「がん診療 UP TO DATE」(がん診療UP TO DATE編集委員会/編著), pp848-860, 日経BP社, 2013
 
13) がん診療UP TO DATE編集委員会:6章-4. 腫瘍崩壊症候群. 「がん診療UP TO DATE」(がん診療UP TO DATE編集委員会/編著), pp902-910, 日経BP社, 2013
 
P.157 掲載の参考文献
1) 松尾清一, 他:ネフローゼ症候群診療指針. 日腎会誌, 53:78-122, 2011
 
2) Ordonez JD, et al:The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int, 44:638-642, 1993
PubMed
3) Ogi M, et al:Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis, 24:427-436, 1994
PubMed
4) Taube D, et al:Depression of normal lymphocyte transformation by sera of patients with minimal change nephropathy and other forms of nephrotic syndrome. Clin Nephrol, 15:286-290, 1981
PubMed
5) Lee JC, et al:The association of cancer and the nephrotic syndrome. Ann Intern Med, 64:41-51, 1966
PubMed
6) 堺 秀人, 他:難治性ネフローゼ症候群(成人例)の診療指針. 日腎会誌, 44:751-761, 2002
 
7)Joel SP, et al:Predicting etoposide toxicity:relationship to organ function and protein binding. J Clin Oncol, 14:257-267, 1996
PubMed
8) Alexandre J, et al:Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy. Ann Oncol, 14:36-41, 2003
PubMed
9) Knight A, et al:Urinary bladder cancer in Wegener's granulomatosis:risks and relation to cyclophosphamide. Ann Rheum Dis, 63:1307-1311, 2004
PubMed
P.164 掲載の参考文献
1) 小山信之:間質性肺炎合併肺癌の治療. 呼吸と循環, 62:1102-1108, 2014
 
2) 「薬剤性肺障害の診断・治療の手引き」(日本呼吸器学会 薬剤性肺障害の診断・治療の手引き作成委員会/編), メディカルレビュー社, 2012
 
3) 佐多将史, 加藤晃史:間質性肺炎・呼吸機能障害を伴う患者. 月刊薬事, 57:1625-1629, 2015
Medical*Online
4) 伊達洋至, 他:肺癌の背景に見られる間質性肺炎をどう診断しマネージするか-外科的立場から-. 肺癌, 55:900-904, 2015
Medical*Online
5) Ohe Y, et al:Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer, 37:54-63, 2001
PubMed
6) Kudoh S, et al:Interstitial lung disease in Japanese patients with lung cancer:a cohort and nested case-control study. Am J Respir Crit Care Med, 177:1348-1357, 2008
PubMed
7) 齋藤好信, 弦間昭彦:抗癌剤による間質性肺炎. 臨床検査, 56:997-1000, 2012
 
8) White DA, et al:Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med, 182:396-403, 2010
PubMed
9) White DA, et al:Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus(RAD001). J Thorac Oncol, 4:1357-1363, 2009
PubMed
10) Yoh K, et al:Severe interstitial lung disease associated with amrubicin treatment. J Thorac Oncol, 5:1435-1438, 2010
PubMed
11) Naidoo J, et al:Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol, 35:709-717, 2017
PubMed
12) 「特発性間質性肺炎診断と治療の手引き 改訂第3版」(日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会/編), p124, 南江堂, 2016
 
13) 弦間昭彦, 他:特発性間質性肺炎合併肺癌に対する化学療法の現況と治療関連急性増悪に関する実態調査. びまん性肺疾患に関する調査研究班. 平成21年度研究報告書:105-107, 2010
 
14) Shukuya T, et al:Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res, 30:4357-4361, 2010
PubMed
15) 峯岸祐司, 他:特発性間質性肺炎合併進行/術後再発肺癌の二次治療以降の化学療法に関する実態調査. びまん性肺疾患に関する調査研究班. 平成24年度研究報告書:87-92, 2013
 
P.172 掲載の参考文献
1) de Torres JP, et al:Lung cancer in patients with chronic obstructive pulmonary disease--incidence and predicting factors. Am J Respir Crit Care Med, 184:913-919, 2011
PubMed
2) Lim JU, et al:Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations. PLoS One, 10:e0142306, 2015
PubMed
3) 山口佳寿博:COPDに合併する呼吸器および他臓器疾患 肺癌. COPD Frontier, 4:87-92, 2005
 
4) Sin DD, et al:Mortality in COPD:Role of comorbidities. Eur Respir J, 28:1245-1257, 2006
PubMed
5) Smith MC & Wrobel JP:Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis, 9:871-888, 2014
PubMed
6) Klastersky J & Paesmans M:The Multinational Association for Supportive Care in Cancer (MASCC) risk index score:10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer, 21:1487-1495, 2013
PubMed
7) Gemma A, et al:Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10708 Japanese patients with non-small-cell lung cancer. Cancer Sci, 105:1584-1590, 2014
 
8) Suter TM & Ewer MS:Cancer drugs and the heart:importance and management. Eur Heart J, 34:1102-1111, 2013
PubMed
9) 「周術期禁煙ガイドライン」(日本麻酔科学会/編), 2015:http://www.anesth.or.jp/guide/pdf/20150409-1guidelin.pdf
 
10) Hughes AN, et al:Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol, 27:1220-1226, 2009
PubMed
11) Kiri VA, et al:Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med, 103:85-90, 2009
PubMed
incidence and predicting factors. Am J Respir Crit Care Med, 184:913-9, 2011
PubMed
P.180 掲載の参考文献
1) Timp JF, et al:Epidemiology of cancer-associated venous thrombosis. Blood, 122:1712-1723, 2013
PubMed
2) Walker AJ, et al:Incidence of venous thromboembolism in patients with cancer-a cohort study using linked United Kingdom databases. Eur J Cancer, 49:1404-1413, 2013
 
3) 澤田 潤, 他:当院の脳血管障害と悪性腫瘍の合併症例に関する検討. 脳卒中, 36:327-332, 2014
Medical*Online
4) Scappaticci FA, et al:Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst, 99:1232-1239, 2007
PubMed
5) Rini BI, et al:Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS):a randomised phase 3 trial. Lancet, 378:1931-1939, 2011
 
6) 「造血器腫瘍診療ガイドライン 2013年版」(日本血液学会/編), pp306-307, 金原出版, 2013
 
7) Gieseler F:Pathophysiological considerations to thrombophilia in the treatment of multiple myeloma with thalidomide and derivates. Thromb Haemost, 99:1001-1007, 2008
PubMed
8) 「Warfarin適正使用情報 第3版」(エーザイ株式会社), pp170-494:http://www.eisai.jp/medical/products/warfarin/proper-use/
 
9) 杉山雄一, 他:薬物動態の変化を伴う薬物間相互作用2012. PharmaTribune, 4:S1, 2012
 
10) 中川原譲二, 他:1. 精神・神経系の病気とくすり-B 中枢系疾患-脳卒中. 薬局, 68:696-707, 2017
 
11) 内山真一郎:I. 障害部位・病態による臨床病型 7. トルーソー症候群. 日内会誌, 97:1805-1808, 2008
 
12) Woerner EM & Rowe RL:Trousseau's syndrome. Am Fam Physician, 38:195-201, 1988
PubMed
13) Farge D, et al:International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost, 11:56-70, 2013
 
14) Lyman GH, et al:Venous thromboembolism prophylaxis and treatment in patients with cancer:American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol, 31:2189-2204, 2013
 
15) 「ベバシズマブ副作用マネジメントガイドライン」(BC Cancer Agency), pp1-2
 
P.188 掲載の参考文献
1) Arakawa K et al:Chemotherapy-induced peripheral neuropathy:Clinical symptoms, managemants and mechanism. Jpn J Pharm Palliat. 4:1-13, 2011
 
2) Brown SJ, et al:Diabetic peripheral neuropathy compromises balance during daily activities. Diabetes Care, 38:1116-1122, 2015
PubMed
3) Oki E, et al:Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial):a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol, 20:767-775, 2015
 
4) Gottschalk PG, et al:Vinca alkaloid neuropathy:nerve biopsy studies in rats and in man. Neurology, 18:875-882, 1968
PubMed
5) 田村和夫:支持療法の進歩 副作用・合併症対策-8. 末梢神経障害. Mebio Oncol, 2:51-58, 2005
 
6) Ongerboer de Visser BW & Tiessens G:Polyneuropathy induced by cisplatin. Prog Exp Tumor Res, 29:190-196, 1985
PubMed
7) Tournigand C, et al:OPTIMOX1:a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. J Clin Oncol, 24:394-400, 2006
 
8) Mielke S, et al:Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res, 11:4843-4850, 2005
PubMed
9) Richardson PG, et al:Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol, 24:3113-3120, 2006
PubMed
10) Richardson PG, et al:Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma:impact of a dose-modification guideline. Br J Haematol, 144:895-903, 2009
PubMed
P.194 掲載の参考文献
1) Szekanecz Z, et al:Gerontology, 57:3-10, 2011
PubMed
2) 加藤裕一, 他:臨床血液, 54:1255, 2013
 
3) Thiers BH, et al:CA Cancer J Clin, 59:73-98, 2009
PubMed
4) Dalakas MC & Hohlfeld R:Lancet, 362:971-982, 2003
PubMed
5) Koh ET, et al:Ann Rheum Dis, 52:857-861, 1993
PubMed
6) Marie I, et al:Br J Dermatol, 162:337-344, 2010
PubMed
7) Keith MP & Gilliland WR:J Clin Rheumatol, 12:199-200, 2006
PubMed
8) Anton E:J Clin Rheumatol, 13:114, 2007
PubMed
9) Hernandez-Rodriguez J, et al:Arch Intern Med, 169:1839-1850, 2009
PubMed
10) Titulaer MJ, et al:Lancet Neurol, 10:1098-1107, 2011
PubMed
11) Nakao YK, et al:Neurology, 59:1773-1775, 2002
PubMed
12) Meriggioli MN & Sanders DB:Lancet Neurol, 8:475-490, 2009
PubMed
13) Skeie GO, et al:Eur J Neurol, 17:893-902, 2010
PubMed
14) 「がん診療UP TO DATE」(がん診療UP TO DATE編集委員会/編著), pp931-932, 日経BP社, 2013
 
15) Titulaer MJ, et al:J Neuroimmunol, 201-202:153-158, 2008
 
16) 「がん診療UP TO DATE」(がん診療UP TO DATE編集委員会/編著), pp964-966, 日経BP社, 2013
 
17) 「がん免疫療法ガイドライン」(日本臨床腫瘍学会/編), pp43-45, 金原出版, 2016
 
P.200 掲載の参考文献
1) Buggia I, et al:Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO(Gruppo Italiano Trapianto di Midollo Osseo).Anticancer Res, 16:2083-2088, 1996
PubMed
2) 5. 移植前処置に使用する薬剤に関する留意事項, 「造血幹細胞移植ガイドライン」(日本造血細胞移植学会/編), p28:https://www.jshct.com/guideline/pdf/06n_zenshochi.pdf
 
3) Sorensen JB, et al:Syndrome of inappropriate secretion of antidiuretic hormone(SIADH)in malignant disease. J Intern Med, 238:97-110, 1995
 
4) Lassman AB & DeAngelis LM:Brain metastases. Neurol Clin, 21:1-23, vii, 2003
 
5) Moscetti L, et al:Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases:survey by Outcome Research Network for Evaluation of Treatment Results in Oncology. Cancer, 109:274-281, 2007
 
6) がん診療UP TO DATE編集委員会:4章-1. 脳転移. 「がん診療UP TO DATE」(がん診療UP TO DATE編集委員会/編著), pp621-622, 日経BP社, 2013
 
7) 「バゾプレシン分泌過剰症(SIADH)の診断と治療の手引き(平成22年度改訂)」(厚生労働科学研究費補助金 難治性疾患克服研究事業), p3, 2011:http://rhhd.info/pdf/001008.pdf
 
8) Forrest JN Jr, et al:Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med, 298:173-177, 1978
PubMed
9) Saito T, et al:Acute aquaresis by the nonpeptide arginine vasopressin(AVP)antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone(SIADH). J Clin Endocrinol Metab, 82:1054-1057, 1997
PubMed
10) Schrier RW, et al:Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med, 355:2099-2112, 2006
PubMed
P.208 掲載の参考文献
1) Weiser MA, et al:Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer, 100:1179-1185, 2004
PubMed
2) Vu K, et al:A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk, 12:355-362, 2012
 
3) Vissers PA, et al:The impact of diabetes on neuropathic symptoms and receipt of chemotherapy among colorectal cancer patients:results from the PROFILES registry. J Cancer Surviv, 9:523-521, 2015
PubMed
4) de la Morena Barrio P, et al:Delayed recovery and increased severity of Paclitaxel-induced peripheral neuropathy in patients with diabetes. J Natl Compr Canc Netw, 13:417-423, 2015
PubMed
5) 日本糖尿病学会:SGLT2阻害薬の適正使用に関するRecommendation:http://www.jds.or.jp/modules/important/index.php?page=article&storyid=48
 
6) Hughes J, et al:Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care, 38:e55-e57, 2015
PubMed
7)KEYTRUDA(R)(pembrolizumab)package insert. Merck社, 2014
 
8) Duval M, et al:Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies:results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood, 99:2734-2739, 2002
 
9) Flinn IW, et al:Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL:the BRIGHT study. Blood, 123:2944-2952, 2014
 
10) Watanabe T, et al:Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma:JCOG 0203 trial. J ClinOncol, 29:3990-3998, 2011
 
11) Bernstein SH, et al:A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma;SWOG 0213. Ann Oncol, 24:1587-1593, 2013
PubMed
12) Yamaguchi M, et al:Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer(NK)/T-cell lymphoma, nasal type:the NK-Cell Tumor Study Group study. J Clin Oncol, 29:4410-4416, 2011
 
13) Rajkumar SV, et al:Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol, 24:431-436, 2006
 
14) Valent P, et al:Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 125:901-906, 2015
PubMed
15) Wu W, et al:The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. In Br J Cancer, 111:628-636, 2014
PubMed
16) Gallo M, et al:Diabetology and oncology meet in a network model:union is strength. Acta Diabetol, 53:515-524, 2016
 
17) Celio L, et al:Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy:a randomized, multicenter, phase III trial. Support Care Cancer, 19:1217-1225, 2011
 
18) BCCA Cancer Drug Manual:http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual/drug-index
 
P.216 掲載の参考文献
1) Khan AA, et al:Diagnosis and management of osteonecrosis of the jaw:a systematic review and international consensus. J Bone Miner Res, 30:3-23, 2015
PubMed
2) Hadji P, et al:Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer:practical guidance for prevention and treatment. Ann Oncol, 22:2546-2555, 2011
PubMed
3) Chien AJ & Goss PE:Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol, 24:5305-5312, 2006
PubMed
4) Eastell R, et al:Effect of anastrozole on bone mineral density:5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol, 26:1051-1057, 2008
PubMed
5) Coates AS, et al:Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:update of study BIG 1-98. J Clin Oncol, 25:486-492, 2007
PubMed
6) Coleman RE, et al:Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study(IES):a randomised controlled study. Lancet Oncol, 8:119-127, 2007
 
7) Jakesz R, et al:Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen:combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 366:455-462, 2005
PubMed
8) Goss PE, et al:Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer:updated findings from NCIC CTG MA. 17. J Natl Cancer Inst, 97:1262-1271, 2005
PubMed
9) Valent P, et al:Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 125:901-906, 2015
PubMed
10) Shahinian VB, et al:Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med, 352:154-164, 2005
PubMed
11) Pfeilschifter J & Diel IJ:Osteoporosis due to cancer treatment:pathogenesis and management. J Clin Oncol, 18:1570-1593, 2000
PubMed
12) 「骨吸収抑制薬関連顎骨壊死の病態と管理:顎骨壊死検討委員会ポジションペーパー 2016」(顎骨壊死検討委員会):http://www.perio.jp/file/news/info_160926.pdf
 
13) NCCN guidelines(R) Prostate Cancer(version 3.2016):https://www.nccn.org/professionals/physician_gls/f_guidelines.asp5
 
14) Coleman R, et al:Bone health in cancer patients:ESMO Clinical Practice Guidelines. Ann Oncol, 25 Suppl 3:iii124-iii137, 2014
 
15) Smith MR, et al:Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med, 361:745-755, 2009
PubMed
16) Ikesue H, et al:Time Course of Calcium Concentrations and Risk Factors for Hypocalcemia in Patients Receiving Denosumab for the Treatment of Bone Metastases From Cancer. Ann Pharmacother, 48:1159-1165, 2014
PubMed
17) FOSAMAX(R)(HIGHLIGHTS OF PRESCRIBING INFORMATION):http://www.merck.com/product/usa/pi_circulars/f/fosamax/fosamax_pi.pdf
 
P.225 掲載の参考文献
1) Hamnvik OP, et al:J Natl Cancer Inst, 103:1572-1587, 2011
PubMed
2) Torino F, et al:Thyroid, 23:1345-1366, 2013
PubMed
3) Blansfield JA, et al:J Immunother, 28:593-598, 2005
PubMed
4) Osorio JC, et al:Ann Oncol, 28:583-589, 2017
PubMed
5) Badros AZ, et al:Am J Med, 112:412-413, 2002
PubMed
6) Figaro MK, et al:Am J Hematol, 86:467-470, 2011
PubMed
7) Illouz F, et al:Eur J Endocrinol, 171:R91-R99, 2014
PubMed
8) Desai J, et al:Ann Intern Med, 145:660-664, 2006
PubMed
9) LENVIMA(TM)(HIGHLIGHTS OF PRESCRIBING INFORMATION):https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206947s000lbl.pdf?et_cid=35470087&et_rid=907466112&linkid=http:%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2015%2f206947s000lbl.pdf
 
10) 「がん免疫療法ガイドライン」(日本臨床腫瘍学会/編), 金原出版, 2016
 
11) Joshi MN, et al:Clin Endocrinol(Oxf), 85:331-339, 2016
PubMed
12) Mandac JC, et al:Hepatology, 43:661-672, 2006
PubMed
13) Carella C, et al:J Clin Endocrinol Metab, 86:1925-1929, 2001
PubMed
14) Centanni M, et al:N Engl J Med, 354:1787-1795, 2006
PubMed
15) Garber JR, et al:Thyroid, 22:1200-1235, 2012
PubMed
16) Bolk N, et al:Arch Intern Med, 170:1996-2003, 2010
PubMed
P.232 掲載の参考文献
1) 林 恭子, 他:薬物性白血球減少症の危険因子及び自覚症状に関する研究. 薬学雑誌, 131:139-152, 2011
 
2) Anderson LA, et al:Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer, 125:398-405, 2009
PubMed
3) Kameda T, et al:Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken), 66:1302-1309, 2014
PubMed
4) Tubach F, et al:Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy:The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum, 60:1884-1894, 2009
PubMed
5) Lee YH, et al:Meta-analysis of genetic polymorphisms in programmed cell death 1. Associations with rheumatoid arthritis, ankylosing spondylitis, and type 1 diabetes susceptibility. Z Rheumatol, 74:230-239, 2015
PubMed
6) Vaidya B, et al:An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. Rheumatology (Oxford), 41:180-183, 2002
PubMed
7) 「今日の治療指針2015」(山口 徹, 北原光夫/監, 福井次矢, 高木 誠, 小室一成/総編集), 医学書院, 2015
 
8) 投与禁忌-3:「関節リウマチ(RA)に対するTNF阻害薬使用ガイドライン(2015年3月12日改訂版)」(日本リウマチ学会):http://www.ryumachi-jp.com/info/guideline_TNF.html
 
P.238 掲載の参考文献
1) Schwartz RN:Anemia in patients with cancer:incidence, causes, impact, management, and use of treatment guidelines and protocols. Am J Health Syst Pharm, 64:S5-13; quiz S28-30, 2007
 
2) Steensma DP:Is anemia of cancer different from chemotherapy-induced anemia? J Clin Oncol, 26:1022-1024, 2008
PubMed
3) Wilson J, et al:A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess, 11:1-202, iii-iv, 2007
 
4) Ludwig H, et al:The European Cancer Anaemia Survey (ECAS):a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer, 40:2293-2306, 2004
PubMed
5) Smith SM, et al:Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia:the University of Chicago series. Blood, 102:43-52, 2003
PubMed
6) Hamaguchi S, et al:Anemia is an independent predictor of long-term adverse outcomes in patients hospitalized with heart failure in Japan. A report from the Japanese Cardiac Registry of Heart Failure in Cardiology(JCARE-CARD). Circ J, 73:1901-1908, 2009
PubMed
7) Groopman JE & Itri LM:Chemotherapy-induced anemia in adults:incidence and treatment. J Natl Cancer Inst, 91:1616-1634, 1999
PubMed
8) Eisenhauer EA, et al:European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer:high-dose versus low-dose and long versus short infusion. J Clin Oncol, 12:2654-2666, 1994
PubMed
9) ten Bokkel Huinink W, et al:Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol, 15:2183-2193, 1997
PubMed
10) Creemers GJ, et al:Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer:results of a large European phase II study. J Clin Oncol, 14:3056-3061, 1996
PubMed
11) Jefferies S, et al:Haematological toxicity of cranio-spinal irradiation. Radiother Oncol, 48:23-27, 1998
PubMed
12) 「[要約]赤血球濃厚液の適正使用」(厚生労働省):http://www.mhlw.go.jp/new-info/kobetu/iyaku/kenketsugo/5tekisei3b01.html
 
13) Jabbour E, et al:Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer, 112:1089-1095, 2008
PubMed
14) Thomas G, et al:Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol, 108:317-325, 2008
PubMed
15) Bohlius J, et al:Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer:a meta-analysis of randomised trials. Lancet, 373:1532-1542, 2009
 
P.246 掲載の参考文献
1) George JN, et al:Drug-induced thrombocytopenia:a systematic review of published case reports. Ann Intern Med, 129:886-890, 1998
 
2) Richardson PG, et al:Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. N Engl J Med 352:2487-2498, 2005
 
3) Ueno H, et al:Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan:GEST study. J Clin Oncol, 31:1640-1648, 2013
PubMed
4) Kitagawa R, et al:Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer:The Open-Label Randomized Phase III Trial JCOG0505. J Clin Oncol, 33:2129-2135, 2015
 
5) De Santis M, et al:Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy:EORTC study 30986. J Clin Oncol, 30:191-199, 2012
PubMed
6) Ohe Y, et al:Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:Four-Arm Cooperative Study in Japan. Ann Oncol, 18:317-323, 2007
PubMed
7) Hanna N, et al:Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol, 24:2038-2043, 2006
PubMed
8) Allegra CJ, et al:Initial safety report of NSABP C-08:A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol, 27:3385-3390, 2009
 
9) Navarro JT, et al:Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia:10,000/microL versus 20,000/microL. Haematologica, 83:998-1000, 1998
 
10) Ogura M, et al:Pilot phase I/II study of new salvage therapy(CHASE)for refractory or relapsed malignant lymphoma. Int J Hematol, 77:503-511, 2003
PubMed
11) Cunningham D, et al:Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma:a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet, 381:1817-1826, 2013
 
12) Mateos MV, et al:Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma:updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol, 28:2259-2266, 2010
 
13) Cines DB & Bussel JB:How I treat idiopathic thrombocytopenic purpura(ITP). Blood, 106:2244-2251, 2005
 
14) Fujimura K, et al:Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol, 81:162-168, 2005
PubMed
15) Diedrich B, et al:A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9)per L versus 30 x 10(9)per L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion, 45:1064-1072, 2005
 
16) Slichter SJ, et al:Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med, 362:600-613, 2010
PubMed
17) Parameswaran R, et al:Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer, 22:1217-1222, 2014
PubMed
18) Kuter DJ:Managing thrombocytopenia associated with cancer chemotherapy. Oncology(Williston Park), 29:282-294, 2015
PubMed
19) 藤村欣吾, 他:成人特発性血小板減少性紫斑病治療の参照ガイド 2012年版. 臨床血液, 53:433-442, 2012
 
P.251 掲載の参考文献
1) Takatoku M, et al:Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol, 78:487-494, 2007
PubMed
2) Smith SM, et al:Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia:the University of Chicago series. Blood, 102:43-52, 2003
PubMed
3) Travis LB, et al:Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med, 340:351-357, 1999
PubMed
4) Greene MH, et al:Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer:a study of five randomized clinical trials. N Engl J Med, 307:1416-1421, 1982
PubMed
5) Kollmannsberger C, et al:Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol, 16:3386-3391, 1998
PubMed
6) Ng A, et al:Treatment-related leukaemia--a clinical and scientific challenge. Cancer Treat Rev, 26:377-391, 2000
PubMed
7) Leone G, et al:The incidence of secondary leukemias. Haematologica, 84:937-945, 1999
PubMed
8) Schanz J, et al:New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes(MDS)and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol, 30:820-829, 2012
PubMed
9) Hashimoto A, et al:Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer. Case Rep Oncol, 7:316-322, 2014
PubMed
10) Hellstrom-Lindberg E, et al:A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor:significant effects on quality of life. Br J Haematol, 120:1037-1046, 2003
PubMed
11) 石井達矢, 他:膀胱原発小細胞癌に対してCPT-11とCBDCAによる全身化学療法を施行した血液透析患者の1例. 日本透析医学会雑誌, 44:79-85, 2011
 
12) Schmitt S, et al:Successful autologous peripheral blood stem cell transplantation in a Jehovah's Witness with multiple myeloma:review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products. Int J Hematol, 87:289-297, 2008
 
13) Santini V & Fenaux P:Treatment of myelodysplastic syndrome with thrombomimetic drugs. Semin Hematol, 52:38-45, 2015
PubMed
P.257 掲載の参考文献
1) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会:第IV章 気道感染症の原因菌とその検出法. 「成人気道感染症診療の基本的考え方」, pp21-26, 2003
 
2) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会:第V章 急性上気道炎, いわゆる"かぜ症候群"の治療方針. 「成人気道感染症診療の基本的考え方」, pp27-33, 2003
 
3) 「呼吸器の病期 A-01かぜ症候群」(日本呼吸器学会):http://www.jrs.or.jp/modules/citizen/index.php?content_id=2
 
4) 保田里美, 他:外来化学療法中止理由からみる, 治療継続を支える看護師の役割. 日本看護学会論文集:看護総合, 44:98-101, 2014
 
5) 「G-CSF適正使用診療ガイドライン2013年版 ver.3」(日本癌治療学会/編), 2016:http://www.jsco-cpg.jp/item/30/index.html
 
6) Sakuma Y, et al:Initial functional status predicts infections during steroid therapy for renal diseases. Clin Nephrol, 63:68-73, 2005
PubMed
7) Stuck AE, et al:Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis, 11:954-963, 1989
PubMed
8) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会:第IV章 気道感染症の原因菌とその検出法. 「成人気道感染症診療の基本的考え方」, p23, 2003
 
9) 高野義久:各科外来治療における耐性菌感染症の実際 呼吸器科-かぜ症候群・急性気管支炎. 治療, 90:2893-2898, 2008
 
10) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会:第VI章 急性気管・気管支炎の治療方針. 「成人気道感染症診療の基本的考え方」, pp34-36, 2003
 
11) Kenealy T & Arroll B:Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev, CD000247, 2013
PubMed
12) 日本臨床腫瘍学会:Clinical Question 27 がん薬物療法を受けている患者にワクチン接種は有効か?「発熱性好中球減少症(FN)診療ガイドライン」(日本臨床腫瘍学会/編), p67, 金原出版, 2012
 
P.265 掲載の参考文献
1) 日本結核病学会:I章 結核の現状. 「結核診療ガイドライン 改訂第3版」(日本結核学会/編), pp1-8, 2015
 
2) 日本結核病学会:II章-6. ハイリスク者の結核. 「結核診療ガイドライン 改訂第3版」(日本結核学会/編), p33, 2015
 
3) 小松彦太郎, 他:肺癌と活動性結核の合併例の検討. 結核, 56:49-55, 1981
 
4) 「非結核性抗酸菌症診療マニュアル」(日本結核病学会/編), pp76-88, 2015
 
5) 日本結核病学会予防委員会・治療委員会:潜在性結核感染症治療指針. 結核, 88:497-512, 2013
Medical*Online
6) Dong YH, et al:Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza:A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials. Chest, 145:1286-1297, 2014
PubMed
7) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med, 161:S221-S247, 2000
PubMed
8) 松山政史, 他:非結核性抗酸菌症の最新知見 免疫-肺MAC症と免疫-. 呼吸, 32:238-243, 2013
 
9) Strayhorn VA, et al:Update on rifampin drug interactions, III. Arch Intern Med, 157:2453-2458, 1997
PubMed
10) 日本結核病学会非結核性抗酸菌症対策委員会, 日本呼吸器学会感染症・結核学術部会:肺非結核性抗酸菌症化学療法に関する見解-2012年改訂. 結核, 87:83-86, 2012
Medical*Online
11) 日本結核病学会:V章 結核の治療. 「結核診療ガイドライン 改訂第3版」(日本結核病学会/編), pp77-96, 2015
 
12) 「非結核性抗酸菌症診療マニュアル」(日本結核病学会/編), pp34-43, 2015
 
13) 藤田 雄, 他:肺癌と活動性非結核性抗酸菌症に対し癌化学療法と抗酸菌治療の同時加療を行った1例. 日呼吸会誌, 49:855-860, 2011
Medical*Online
14) 森 雅秀, 他:非結核性抗酸菌症と非小細胞肺癌が同時に発見され抗酸菌治療と癌化学療法を並行して行った2症例. 日胸, 67:613-621, 2008
Medical*Online
15) [NCCN clinical praciice guidelines in oncology:Prevention and Treatment of Cancer-Related Infections (version 2.2016)](NCCN):https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf
 
P.272 掲載の参考文献
1) Ho WL, et al:The ophthalmological complications of targeted agents in cancer therapy:what do we need to know as ophthalmologists? Acta Ophthalmol, 91:604-609, 2013
PubMed
2) 日本緑内障学会:緑内障診療ガイドライン 第3版. 日眼会誌, 116:65, 2011
 
3) Zetterberg M & Celojevic D:Gender and cataract--the role of estrogen. Curr Eye Res, 40:176-190, 2015
PubMed
4) Howell A, et al:Results of the ATAC(Arimidex, Tamoxifen, Alone or in Combination)trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet, 365:60-62, 2005
 
5) 鈴木茂伸:視力障害. 日本臨床, 72:565-569, 2014
Medical*Online
6) Pavlidis NA, et al:Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer, 69:2961-2964, 1992
PubMed
7) 柏木賢治:ステロイド点眼薬の眼科的副作用. あたらしい眼科, 25:437-442, 2008
Medical*Online
8) 「ステロイド薬の選び方と使い方」(矢野三郎/監, 佐藤文三/編), 南江堂, 1999
 

第3章 見過ごせない臨床背景とがん薬物療法

P.278 掲載の参考文献
1) 「術後感染予防抗菌薬適正使用のための実践ガイドライン」(公益社団法人日本化学療法学会・一般社団法人日本外科感染症学会 術後感染予防抗菌薬適正使用に関するガイドライン作成委員会/編), 日本化学療法学会, 2016
 
2) Bratzler DW, et al:Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm, 70:195-283, 2013
 
3) Lee AY & Levine MN:The thrombophilic state induced by therapeutic agents in the cancer patient. Semin Thromb Hemost, 25:137-145, 1999
PubMed
4) 循環器病の診断と治療に関するガイドライン(2008年度合同研究班報告), 肺血栓塞栓症および深部静脈血栓症の診断, 治療, 予防に関するガイドライン(2009年改訂版)http://www.j-circ.or.jp/guideline/pdf/JCS2009_andoh_h.pdf(2017年7月閲覧)
 
P.287 掲載の参考文献
1) Budha NR, et al:Drug absorption interactions between oral targeted anticancer agents and PPIs:is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther, 92:203-213, 2012
PubMed
2) Collado-Borrell R, et al:Oral antineoplastic agent interactions with medicinal plants and food:an issue to take into account. J Cancer Res Clin Oncol, 142:2319-2330, 2016
PubMed
3) Yin OQ, et al:Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol, 50:188-194, 2010
PubMed
4) Parsad S & Ratain MJ:Food Effect Studies for Oncology Drug Products. Clin Pharmacol Ther, 101:606-612, 2017
PubMed
5) Sprowl JA & Sparreboom A:Uptake carriers and oncology drug safety. Drug Metab Dispos, 42:611-622, 2014
PubMed
6) 大野能之:第1章-1 抗がん剤の相互作用.「がん化学療法レジメン管理マニュアル」(濱 敏弘/監, 青山 剛, 他/編), pp2-11, 医学書院, 2012
 
7) Valachis A, et al:Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality:a population-based study. Breast Cancer Res Treat, 159:293-303, 2016
PubMed
8) Donneyong MM, et al:Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors:multi-database cohort study. BMJ, 354:i5014, 2016
PubMed
9) Nozaki Y, et al:Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J Pharmacol Exp Ther, 309:226-234, 2004
PubMed
10) Thyss A, et al:Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet, 1:256-258, 1986
PubMed
11) Posada MM, et al:Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling. Drug Metab Dispos, 43:325-334, 2015
PubMed
12) Kawazoe H, et al:Non-steroidal anti-inflammatory drugs induce severe hematologic toxicities in lung cancer patients receiving pemetrexed plus carboplatin:A retrospective cohort study. PLoS One, 12:e0171066, 2017
PubMed
P.293 掲載の参考文献
1) 「高齢者の安全な薬物療法ガイドライン2015」(日本老年医学会, 他/編), p12-16, 165-170, メジカルビュー社, 2015
 
2) the American Geriatrics Society 2015 Beers Criteria Update Expert Panel:American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc, 63:2227-2246, 2015
 
3) O'Mahony D, et al:STOPP/START criteria for potentially inappropriate prescribing in older people:version 2. Age Ageing, 44:213-218, 2015
 
4) LeBlanc TW, et al:Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol, 16:e333-e341, 2015
PubMed
5) Sharma M, et al:Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol, 7:346-353, 2016
 
6) Hurria A, et al:Predicting chemotherapy toxicity in older adults with cancer:a prospective multicenter study. J Clin Oncol, 29:3457-3465, 2011
 
7) Extermann M, et al:Predicting the risk of chemotherapy toxicity in older patients:the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer, 118:3377-3386, 2012
 
8) Woopen H, et al:The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer. Gynecol Oncol, 140:554-558, 2016
PubMed
9) Greenlee H, et al:Association Between Complementary and Alternative Medicine Use and Breast Cancer Chemotherapy Initiation:The Breast Cancer Quality of Care (BQUAL) Study. JAMA Oncol, 2:1170-1176, 2016
PubMed
10) Scott IA, et al:Reducing inappropriate polypharmacy:the process of deprescribing. JAMA Intern Med, 175:827-834, 2015
 
11) Lees J & Chan A:Polypharmacy in elderly patients with cancer:clinical implications and management. Lancet Oncol, 12:1249-1257, 2011
PubMed
12) Tinetti ME, et al:Association between guideline recommended drugs and death in older adults with multiple chronic conditions:population based cohort study. BMJ, 351:h4984, 2015
PubMed
13) Reeve E, et al:Patient barriers to and enablers of deprescribing:a systematic review. Drugs Aging, 30:793-807, 2013
PubMed
14) Jou J & Johnson PJ:Nondisclosure of Complementary and Alternative Medicine Use to Primary Care Physicians:Findings From the 2012 National Health Interview Survey. JAMA Intern Med, 176:545-546, 2016
PubMed
15) Nightingale G, et al:Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol, 33:1453-1459, 2015
 

第4章 特殊な臨床背景でのがん薬物療法

P.300 掲載の参考文献
1) Smith TJ, et al:Recommendations for the Use of WBC Growth Factors:American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol, 33:3199-3212, 2015
 
2) NCCN Clinical Practice Guidelines in Oncology-Myeloid growth factors:version 2, 2016
 
3) Loupakis F, et al:Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med, 371:1609-1618, 2014
PubMed
4) Okusaka T, et al:Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Sci, 105:1321-1326, 2014
PubMed
5) Juliusson G, et al:Age and acute myeloid leukemia:real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood, 113:4179-4187, 2009
PubMed
6) Burnett AK, et al:A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 109:1114-1124, 2007
 
7) Tilly H, et al:Diffuse large B-cell lymphoma (DLBCL):ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 26 Suppl 5:v116-v125, 2015
 
8) 「EBMの手法による肺癌診療ガイドライン2016年」(日本肺癌学会), II. 非小細胞肺癌-5-4. 非扁平上皮癌, EGFR遺伝子高感受性変異:https://www.haigan.gr.jp/guideline/2016/1/2/160102050100.html#s_1_2_5-4
 
9) Inoue A, et al:First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol, 27:1394-1400, 2009
PubMed
10) Kudoh S, et al:Interstitial lung disease in Japanese patients with lung cancer:a cohort and nested case-control study. Am J Respir Crit Care Med, 177:1348-1357, 2008
PubMed
11) 「大腸癌治療ガイドライン 医師用 2016年版」(大腸癌研究会/編), pp31-38, 2016
 
12) 「卵巣がん治療ガイドライン 2015年版」(日本婦人科腫瘍学会/編), pp82-83, 2015
 
P.307 掲載の参考文献
1) 「用語集(2013年版)」(日本癌治療学会用語・ICD-11委員会):http://www.jsco.or.jp/jpn/user_data/upload/File/yougo13.pdf
 
2) 「大腸癌取扱い規約 第8版」(大腸癌研究会/編), P18, 金原出版, 2013
 
3) Tachimori Y, et al:The Registration Committee for Esophageal Cancer of the Japan Esophageal Society:Comprehensive registry of esophageal cancer in Japan. Esophagus, 12:101-129, 2015
 
4) 十名理紗, 他:頭頸部扁平上皮癌における重複癌の検討. 耳鼻咽喉科臨床, 106:155-160, 2013
 
5) 西村幸寿, 他:胃癌に合併する重複癌の臨床的検討. 癌と化学療法, 39:2301-2303, 2013
 
6) 近藤竜一, 他:原発性肺癌切除例における他臓器重複癌の検討. 肺癌, 48:33-38, 2008
Medical*Online
7) Kato T, et al:Multiple primary malignancies involving primary sporadic colorectal cancer in Japan:incidence of gastric cancer with colorectal cancer patients may be higher than previously recognized. World J Surg Oncol, 13:23, 2015
PubMed
8) 須藤 剛, 他:他臓器重複大腸癌の臨床病理学的検討. 日本大腸肛門病学会誌, 62:82-88, 2009
 
9) 塩澤 学, 他:大腸癌における他臓器重複癌の検討. 日本消化器外科学会誌, 40:1557-1564, 2007
 
10) 石黒めぐみ, 他:大腸癌に合併する多発癌・重複がんに関するフォローアップについて. 日本大腸肛門病会誌, 59:863-868, 2006
 
11) 島谷英彦, 他:大腸他臓器重複癌症例の検討. 日本大腸肛門病会誌, 56:294-298, 2003
 
12) 高橋周作, 他:大腸癌と他臓器重複癌の臨床病理学的検討. 日本臨床外科会誌, 64:2677-2681, 2003
 
13) 湖山信篤, 他:他臓器の癌を重複した大腸癌症例の検討:重複癌が大腸癌の治療成績に及ぼす影響について:日本臨床外科会誌, 62:874-878, 2001
 
14) 西尾正道, 他:頭頸部多重癌の臨床(放射線科の立場より). 頭頸部腫瘍, 29:515-520, 2003
 
15) Salah-Eddin A, et al:Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin Plus Either Oxaliplatin or Cisplatin:A Study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol, 26:1435-1442, 2008
PubMed
P.313 掲載の参考文献
1) Li J & Gwilt P:The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol, 50:373-382, 2002
PubMed
2) Evans WE & Pratt CB:Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther, 23:68-72, 1978
PubMed
3) 井藤達也, 他:肺癌患者における塩酸イリノテカン(CPT-11)の胸水中および心嚢液中への移行性. 臨床薬理, 33:47-52, 2002
 
4) Savaraj N, et al:Pharmacology of mitoxantrone in cancer patients. Cancer Chemother Pharmacol, 8:113-117, 1982
PubMed
5) Donehower RC, et al:Sequential methotrexate and 5-fluorouracil in advanced ovarian carcinoma. Gynecol Oncol, 27:90-96, 1987
PubMed
6) Dickgreber NJ, et al:Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clin Cancer Res, 16:2872-2880, 2010
PubMed
7) Honore PH, et al:Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients. Cancer Chemother Pharmacol, 74:349-357, 2014
PubMed
8) Shiozawa T, et al:Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy:a postmarketing survey. Jpn J Clin Oncol, 43:483-491, 2013
PubMed
9) 小川一誠, 他:Mitoxantroneの生体内動態に関する研究. 癌と化学療法, 13:3028-3033, 1986
Medical*Online
10) Mahadevan A, et al:Third space sequestration increases toxicity of fludarabine--a case report. Acta Oncol, 36:441, 1997
PubMed
11) Herrstedt J, et al:Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancer. Eur J Cancer, 28A:1070-1073, 1992
PubMed
12) Smolle E, et al:Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer Res, 34:1553-1561, 2014
PubMed
13) Bradshaw M, et al:The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep, 15:207-216, 2013
PubMed
14) 滝口裕一:悪性胸水. 「新臨床腫瘍学 第4版」(日本臨床腫瘍学会/編), pp591-593, 2015
 
15) 平島詳典:悪性腹水. 「新臨床腫瘍学 第4版」(日本臨床腫瘍学会/編), pp597-599, 2015
 
16) DeCamp MM Jr, et al:Malignant effusive disease of the pleura and pericardium. Chest, 112:291S-295S, 1997
PubMed
P.323 掲載の参考文献
1) Sonis ST:A biological approach to mucositis. J Support Oncol, 2:21-32;discussion 35-6, 2004
 
2) Elting LS, et al:The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer, 98:1531-1539, 2003
 
3) Dewys WD, et al:Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med, 69:491-497, 1980
 
4) 「頭頸部がんの化学放射線療法」(丹生健一, 他/編), 日本看護協会出版会, pp38, 48, 2015
 
5) Jensen SB, et al:A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies:prevalence, severity and impact on quality of life. Support Care Cancer, 18:1039-1060, 2010
PubMed
6) Forastiere AA, et al:Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med, 349:2091-2098, 2003
PubMed
7) Adelstein DJ, et al:An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol, 21:92-98, 2003
PubMed
8) Bonner JA, et al:Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354:567-578, 2006
PubMed
9) Pointreau Y, et al:Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst, 101:498-506, 2009
 
10) Vermorken JB, et al:Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med, 357:1695-1704, 2007
PubMed
11) Posner MR, et al:Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med, 357:1705-1715, 2007
 
12) Lilleby K, et al:A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant, 37:1031-1035, 2006
PubMed
13) Mori T, et al:Excretion of cytosine arabinoside in saliva after its administration at high doses. Anticancer Drugs, 17:597-598, 2006
PubMed
14) Matsuda C, et al:Double-blind, placebo-controlled, randomized phase II study of TJ-14(Hangeshashinto)for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. Cancer Chemother Pharmacol, 76:97-103, 2015
PubMed
15) 杉崎崇人, 他:頭頸部腫瘍Docetaxel/Cisplatin/Fluorouracil(DCF)療法による口内炎に対するポラプレジンク-アルギン酸ナトリウム混合液(P-AG液)の予防的効果. 癌と化学療法, 38:783-787, 2011
Medical*Online
16) 米澤理可, 他:婦人科癌化学療法における食欲不振に対する六君子湯の効果. 産婦人科漢方研究のあゆみ, 30:20-24, 2013
Medical*Online
P.331 掲載の参考文献
1) Connolly GC & Khorana AA:Emerging risk stratification approaches to cancer-associated thrombosis:risk factors, biomarkers and a risk score. Thromb Res, 125 Suppl 2:S1-S7, 2010
 
2) Furlan M, et al:von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med, 339:1578-1584, 1998
PubMed
3) Khorana AA, et al:Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol, 24:484-490, 2006
PubMed
4) Scappaticci FA, et al:Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst, 99:1232-1239, 2007
PubMed
5) Nalluri SR, et al:Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients:a meta-analysis. JAMA, 300:2277-2285, 2008
PubMed
6) Fisher B, et al:Doxorubicin-containing regimens for the treatment of stage II breast cancer:The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol, 7:572-582, 1989
PubMed
7) Albain KS, et al:Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer:a phase 3, open-label, randomised controlled trial. Lancet, 374:2055-2063, 2009
PubMed
8) Decensi A, et al:Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation, 111:650-656, 2005
 
9) Rajkumar SV, et al:Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol, 24:431-436, 2006
 
10) Weber DM, et al:Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med, 357:2133-2142, 2007
PubMed
11) van Zaane B, et al:Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J Thromb Haemost, 8:2483-2493, 2010
PubMed
12) Giles FJ, et al:Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy:a retrospective cohort analysis. Leukemia, 27:1310-1315, 2013
PubMed
13) Grace RF, et al:The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol, 152:452-459, 2011
 
14) Sanz MA, et al:Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy:a multicenter study by the PETHEMA group. Blood, 103:1237-1243, 2004
PubMed
15) Levade M, et al:Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood, 124:3991-3995, 2014
PubMed
16) Lyman GH, et al:Venous thromboembolism prophylaxis and treatment in patients with cancer:American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol, 31:2189-2204, 2013
 
17) Wells PS, et al:Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med, 349:1227-1235, 2003
PubMed
P.337 掲載の参考文献
1) 「骨吸収抑制薬関連顎骨壊死の病態と管理:顎骨壊死検討委員会ポジションペーパー 2016」(顎骨壊死検討委員会):http://www.perio.jp/file/news/info_160926.pdf
 
2) Mavrokokki T, et al:Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg, 65:415-423, 2007
PubMed
3) Saad F, et al:Incidence, risk factors, and outcomes of osteonecrosis of the jaw:integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol, 23:1341-1347, 2012
PubMed
4) Vahtsevanos K, et al:Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol, 27:5356-5362, 2009
PubMed
5) Fehm T, et al:Bisphosphonate-induced osteonecrosis of the jaw(ONJ):Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol, 112:605-609, 2009
PubMed
6) Kyrgidis A, et al:Bisphosphonate-related osteonecrosis of the jaws:a case-control study of risk factors in breast cancer patients. J Clin Oncol, 26:4634-4638, 2008
PubMed
7) Yoneda T, et al:Bisphosphonate-related osteonecrosis of the jaw:position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab, 28:365-383, 2010
PubMed
8) Marx RE, et al:Bisphosphonate-induced exposed bone(osteonecrosis/osteopetrosis)of the jaws:risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg, 63:1567-1575, 2005
PubMed
9) Guarneri V, et al:Bevacizumab and osteonecrosis of the jaw:incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat, 122:181-188, 2010
PubMed
10) Christodoulou C, et al:Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology, 76:209-211, 2009
PubMed
11) BC Cancer Agency:Oral/Dental Care Patients During Chemotherapy:http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines/head-neck/oral-dental-care
 
12) Rankin KV, et al:Oral health in Cancer Therapy. Texas Cancer Council, 1-66, 1999
 
13) 「重篤副作用疾患別対応マニュアル ビスホスホネート系薬剤による顎骨壊死」(厚生労働省), pp13-14:http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1l01.pdf
 
P.344 掲載の参考文献
1) Huscher D, et al:Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis, 68:1119-1124, 2009
PubMed
2) Van Staa TP, et al:Use of oral corticosteroids and risk of fractures. J Bone Miner Res, 15:993-1000, 2000
PubMed
3)Ragab AH, et al:Osteoporotic fractures secondary to methotrexate therapy of acute leukemia in remission.Cancer, 25:580-585, 1970
PubMed
4) Powles TJ, et al:Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol, 14:78-84, 1996
 
5) Hadji P:Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol, 69:73-82, 2009
PubMed
6) Smith MR, et al:Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer:effects on bone mineral density and body composition. J Clin Oncol, 22:2546-2553, 2004
 
7) Maie K, et al:Aprepitant does not alter prednisolone pharmacokinetics in patients treated with R-CHOP. Ann Oncol, 25:298-299, 2014
PubMed
8) 日本癌治療学会:Clinical Question 2 がん薬物療法後の急性の悪心・嘔吐をどのように予防するか. 「制吐薬適正使用ガイドライン2015年10月【第2版】」(日本癌治療学会/編), pp36-40, 金原出版, 2015
 
9) Horvat TZ, et al:Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol, 33:3193-3198, 2015
 
10) 日本臨床腫瘍学会:Clinical Question 23 がん薬物療法時の抗菌薬の予防投与はFNの発症予防に有用か?「発熱性好中球減少症(FN)診療ガイドライン」(日本臨床腫瘍学会/編), pp56-57, 金原出版, 2012
 
11) 深在性真菌症のガイドライン作成委員会:第1章 深在性真菌症の診断と治療のフローチャート. 「深在性真菌症の診断・治療ガイドライン2014」(深在性真菌症のガイドライン作成委員会/編), pp1-9, 協和企画, 2014
 
12) Sandherr M, et al:Antiviral prophylaxis in patients with haematological malignancies and solid tumours:Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol, 17:1051-1059, 2006
PubMed
13) 日本臨床腫瘍学会:Clinical Question 26 どのような患者にニューモシスチス肺炎の予防は有効か?「発熱性好中球減少症(FN)診療ガイドライン」(日本臨床腫瘍学会/編), pp65-66, 金原出版, 2012
 
14) Hashimoto K, et al:Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma, 51:1816-1821, 2010
PubMed
15) Suzuki Y, et al:Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research:2014 update. J Bone Miner Metab, 32:337-350, 2014
PubMed

書評

最近チェックした商品履歴

Loading...